![]() ![]() ![]() The company had revenue of $44.36 million during the quarter, compared to analysts’ expectations of $18.41 million. ![]() The biopharmaceutical company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.28. Get Fate Therapeutics alerts:įate Therapeutics ( NASDAQ:FATE – Get Rating) last posted its quarterly earnings data on Tuesday, February 28th. Finally, SVB Leerink dropped their target price on Fate Therapeutics from $62.00 to $10.00 and set an “outperform” rating on the stock in a report on Friday, January 6th. lowered Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 10th. Wedbush lowered Fate Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $42.00 to $7.00 in a report on Friday, January 6th. Cowen cut Fate Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Friday, January 6th. Citigroup upped their price objective on Fate Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, March 2nd. Several research firms have recently weighed in on FATE. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $20.36. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and six have given a buy rating to the company. ( NASDAQ:FATE – Get Rating) have received a consensus rating of “Hold” from the twenty-three research firms that are presently covering the stock, MarketBeat reports. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |